Seeking Alpha

Threshold Pharma (THLD) -24.2% premarket after disclosing its recent Phase 2b clinical...

Threshold Pharma (THLD) -24.2% premarket after disclosing its recent Phase 2b clinical trial of the investigational hypoxia-targeted drug TH-302 in combination with Gemcitabine boosted the survival of pancreatic patients but only by 4.5% - not enough to be statistically significant.
Comments (5)
  • Quick Research
    , contributor
    Comments (4) | Send Message
     
    Wasn't the goal of the study anyway...
    17 Sep 2012, 10:10 AM Reply Like
  • GaryLee276
    , contributor
    Comments (141) | Send Message
     
    I am lost on this one?
    17 Sep 2012, 12:09 PM Reply Like
  • TruffelPig
    , contributor
    Comments (4059) | Send Message
     
    This is wrong reporting. The MOS increased from 6 to 9 months (in line with improvement in progression free time) but due to small numbers the result was not statistical significant. Small phase II studies frequently are not designed to show MOS improvement. Same thing happened to ECYT - it fell from $10 to $3 - I bought a ton. Look where the stock is now.

     

    I bought THLD today because I got a 20% discount on the shares because the market judged results wrong. Thank you market!
    17 Sep 2012, 08:33 PM Reply Like
  • Maria Auziliadora
    , contributor
    Comments (628) | Send Message
     
    Truffe you are completely right and I saw what happened to ECYT and bought there too THLD will keep going up
    20 Sep 2012, 05:25 AM Reply Like
  • Maria Auziliadora
    , contributor
    Comments (628) | Send Message
     
    Truffe it seems that we like the same stocks I definitely do my homework and I can see you do too :)
    20 Sep 2012, 05:36 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|